Orexo Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Public

  • Employees
  • 113

Employees

  • Stock Symbol
  • ORX

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $1.54
  • (As of Tuesday Closing)

Orexo General Information

Description

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Contact Information

Website
www.orexo.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Virdings Allé 32 A
  • 754 50 Uppsala
  • Sweden
+46 018-780
Primary Industry
Pharmaceuticals
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Virdings Allé 32 A
  • 754 50 Uppsala
  • Sweden
+46 018-780

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Orexo Stock Performance

As of 11-Feb-2025, Orexo’s stock price is $1.54. Its current market cap is $53M with 34.5M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.54 $1.62 $0.83 - $2.24 $53M 34.5M 42K -$0.56

Orexo Financials Summary

As of 31-Dec-2024, Orexo has a trailing 12-month revenue of $55.8M.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 102,206 102,206 80,179 70,734
Revenue 55,787 55,787 60,099 61,539
EBITDA 4,624 4,624 (3,058) (7,679)
Net Income (19,195) (19,195) (12,071) (17,506)
Total Assets 53,909 53,909 78,708 106,310
Total Debt 43,141 43,141 47,409 51,726
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Orexo Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Orexo‘s full profile, request access.

Request a free trial

Orexo Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Phar
Pharmaceuticals
Uppsala, Sweden
113 As of 2024

Cambridge, United Kingdom
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Orexo Competitors (12)

One of Orexo’s 12 competitors is AstraZeneca, a Formerly PE-Backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AstraZeneca Formerly PE-Backed Cambridge, United Kingdom
Sun Pharmaceutical Industries Corporation Mumbai, India
Novartis India Corporation Mumbai, India
Targanta Therapeutics Corporation Corporation Parsippany, NJ
Novartis Corporation Basel, Switzerland
You’re viewing 5 of 12 competitors. Get the full list »

Orexo Patents

Orexo Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202319899-D0 New composition Pending 22-Dec-2023
GB-202315885-D0 New composition Pending 17-Oct-2023
GB-202308121-D0 New composition Pending 31-May-2023
GB-202308123-D0 New copmosition Pending 31-May-2023
GB-202213306-D0 New pharmaceutical composition Inactive 12-Sep-2022
To view Orexo’s complete patent history, request access »

Orexo Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orexo Acquisitions (3)

Orexo’s most recent deal was a Merger/Acquisition with PharmaKodex for . The deal was made on 21-Aug-2009.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
PharmaKodex 21-Aug-2009 Merger/Acquisition Pharmaceuticals
Biolipox 23-Nov-2007 Merger/Acquisition Drug Discovery
CePep 29-Aug-2003 Merger/Acquisition Biotechnology
To view Orexo’s complete acquisitions history, request access »

Orexo ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

38.92 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Pharmaceuticals

Subindustry

of 425

Rank

Percentile

To view Orexo’s complete esg history, request access »

Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Biolipox Solna, Sweden 2000

Orexo FAQs

  • When was Orexo founded?

    Orexo was founded in 1995.

  • Where is Orexo headquartered?

    Orexo is headquartered in Uppsala, Sweden.

  • What is the size of Orexo?

    Orexo has 113 total employees.

  • What industry is Orexo in?

    Orexo’s primary industry is Pharmaceuticals.

  • Is Orexo a private or public company?

    Orexo is a Public company.

  • What is Orexo’s stock symbol?

    The ticker symbol for Orexo is ORX.

  • What is the current stock price of Orexo?

    As of 11-Feb-2025 the stock price of Orexo is $1.54.

  • What is the current market cap of Orexo?

    The current market capitalization of Orexo is $53M.

  • What is Orexo’s current revenue?

    The trailing twelve month revenue for Orexo is $55.8M.

  • Who are Orexo’s competitors?

    AstraZeneca, Sun Pharmaceutical Industries, Novartis India, Targanta Therapeutics Corporation, and Novartis are some of the 12 competitors of Orexo.

  • What is Orexo’s annual earnings per share (EPS)?

    Orexo’s EPS for 12 months was -$0.56.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »